We are pleased to announce that ThyroSeq® Genomic Classifier is now available from UPMC (University of Pittsburgh) 

ThyroSeq® Genomic Classifier – Patient Information

What is ThyroSeq®?

ThyroSeq® is an advanced molecular test designed to evaluate thyroid nodules with uncertain results of thyroid nodules assessment classified as indeterminate (Bethesda III or IV), which often lead to surgery such as lobectomy or thyroidectomy.

By analyzing genetic alterations in thyroid cells, ThyroSeq® helps determine the likelihood of a nodule being benign or malignant, providing valuable insights before surgery is considered.

Why is ThyroSeq® Important?

  • Accuracy: Increases diagnostic accuracy for thyroid nodules.
  • Minimally Invasive and Prevents Unnecessary Surgery: ThyroSeq® identifies benign nodules, helping to avoid unnecessary thyroid surgeries.
  • Precision Diagnosis: It detects key genetic mutations linked to thyroid cancer, providing a clear diagnosis.
  • Personalized Treatment for thyroid nodules with uncertain results from previous tests Bethesda V or VI: For malignant or high-risk nodules, ThyroSeq® offers insights into prognosis, including cancer recurrence risk assessment, and provides targeted treatment options based on genomic information.
  • Peace of Mind: Helps alleviate anxiety regarding potential thyroid cancer.

How is my sample collected for ThyroSeq® test?

Cells are collected during a Fine Needle Aspiration (FNA) procedure. A sample is taken from the thyroid nodule.

Cytology slides from a previously performed FNA procedure are acceptable for testing.

How Does the Process Work?

  1. ThyroSeq Can be performed using fixed cytology smears
  2. Sample Analysis at UPMC (University of Pittsburgh Medical Center, USA): The specimen is sent for genetic testing.
  3. Detailed Report: A comprehensive report is provided to your physician, guiding the best treatment approach.

Who Can Benefit from ThyroSeq®?

  • Patients with indeterminate (uncertain results) of thyroid nodules assessment.
  • Patients with previous inconclusive biopsy results.
  • Patient with confirmed malignancy and considering surgery or treatment recommendation but seeking a more precise diagnosis before proceeding.
  • Patients who require further evaluation of thyroid nodules previously diagnosed as benign.

How Accurate is ThyroSeq®?

  • Sensitivity: 94% (ability to detect cancer).
  • Specificity: 82% (ability to confirm benign nodules).
  • Negative Predictive Value (NPV): 97% (high confidence in ruling out malignancy).

What does Thyroseq accreditation entail?

  • CLIA Certification: ThyroSeq is performed in laboratories accredited under the Clinical Laboratory Improvement Amendments (CLIA), ensuring high standards of quality and reliability.

  • CAP Accreditation: Many facilities, including UPMC, accredited by the College of American Pathologists (CAP), further assuring the quality of testing.

What is the practical experience of the Thyroseq team?

  • Qualified Personnel: The testing is conducted by experienced pathologists and geneticists who specialize in thyroid pathology.
  • Ongoing Training: Staff undergo continuous education and training to stay updated on the latest advancements in genomic testing and best practices.
  • Clinical Practice: The laboratory has a proven track record of successfully processing and interpreting ThyroSeq tests, contributing to accurate diagnosis and patient management

Validation:

Additional Information:

  • If your doctor recommends ThyroSeq, you can proceed by contacting us
  • If you decide to do the test, Patients are required to prepay for the test in case you are a self-pay
  • To finalise the order of your test, your doctor will send your ThyroSeq request to us. A representative will contact you to make full payment to complete your test request.
  • ThyroSeq is a private service, and currently, no financial support is available to cover the cost, including for Thiqa patients. Patients with private insurance should check with their provider regarding potential coverage.
  • Your sample will be collected and sent to UPMC for analysis by DHL.
  • After your sample is collected, results will be available in approximately 21 days
  •  Your doctor will review the findings with you and discuss the next steps for your treatment plan.
  • Your healthcare provider will discuss the results and next steps once they are available.
  • Should the sample fail to generate a result, the patient will be offered a re-test at no additional cost.

Contact Information

For ThyroSeq Inquiries

  • Phone: +971 58 53 16450
  • Email: info@careontime.net

For more details, consult your endocrinologist or visit [www.ThyroSeq.com].